Medical Research · us
Why Do Blood Counts Remain Low After CAR-T? Study Points to Hematopoietic Cell Clone Expansion and Bone Marrow Inflammation
Even after lymphoma goes into remission, recovery of the blood and immune systems can be prolonged. A new study links hematopoietic cell clone expansion and persistent inflammation to low blood counts and secondary blood cancers after CAR-T treatment, but causality remains unclear.
For patients with lymphoma receiving CAR-T cell therapy, bringing the tumor under control does not necessarily mean the effects of treatment are behind them. Some patients have persistently low blood counts and slow recovery of immune function, while also facing risks of infection and secondary hematologic malignancies. A new study turns to the bone marrow to explore whether interconnected biological mechanisms underlie these problems.
The study, published online in *Nature Genetics* on November 2, analyzed patients with lymphoma who received CD19-targeted CAR-T therapy. It found that hematopoietic cell clones carrying genetic variants often expanded after infusion and were associated with poorer immune reconstitution and therapy-related myeloid malignancies. A 2025 preprint of the same study, included in Stanford Medicine’s records, also documented these main observations; the two are different publication versions of the same study, rather than independent validation.
“Clonal hematopoiesis” refers to hematopoietic cells carrying specific genetic variants and their descendants gradually accounting for a larger proportion of the blood cell population. It does not itself mean blood cancer, but it may offer clues for tracking changes in the blood-forming system. Using propensity score matching, the researchers compared CAR-T patients with patients who underwent autologous hematopoietic stem cell transplantation and found poorer immune reconstitution and more infections in the former group. This matching helps reduce some differences between groups but cannot rule out all confounding factors.
Bone marrow analysis revealed another relationship: prolonged low blood counts after treatment were associated with “clonal cytopenia of undetermined significance” (CCUS) and accompanied by interferon-mediated inflammatory signaling. This led the researchers to propose that abnormal cell clones may expand in a persistently inflamed bone marrow environment. However, these observations cannot establish whether inflammation promotes clonal expansion, the clones alter the bone marrow environment, or both are influenced by shared factors.
According to the published paper as cited by AgingResearch.News, the team screened 533 patients with non-Hodgkin lymphoma who received CAR-T at Stanford and identified 17 patients with therapy-related myeloid malignancies. These counts help convey the scale of the study, but they cannot be used directly as an estimate of individual risk for all CAR-T patients, much less prove that CAR-T itself caused these cancers.
The study’s comparisons were also limited by the treatment context. Factors listed in the paper include exposure to COVID-19 during the pandemic, exceptionally good treatment outcomes in the autologous transplantation comparison group, and the additional use of CD22-targeted CAR-T in some Stanford patients who relapsed, which may affect the risk of myeloid malignancies. Patients’ prior treatments and subsequent disease courses also make it harder to isolate the contribution of any single factor.
The value of this study lies in posing more specific questions for long-term toxicity monitoring: could genetic changes in hematopoietic cells, clone size, and bone marrow inflammation together help identify patients whose recovery is slower? The current findings offer directions for research on monitoring and prevention, but they have not established screening thresholds ready for direct use, nor have they shown that suppressing inflammation or intervening in clonal expansion can reduce infections or secondary blood cancers.